Journal profile · Biochemistry, Genetics and Molecular Biology-Biochemistry, Genetics and Molecular Biology (miscellaneous)
MedComm - Oncology
ISSN 2769-6448 · Wiley · Australia
MedComm - Oncology: CAS Zone 4 · Medicine (2026 Xinrui edition); impact factor 8.5 (journal website); fully open access; APC about USD 2,600; median 127 days to acceptance (90 articles, last 24 months); acceptance rate 25% (journal website); 51 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
MedComm - Oncology is published by Wiley and is classed under Medicine in the CAS Journal Ranking. By OpenAlex counts of its recent articles, its largest topics are Cancer Immunotherapy and Biomarkers, Cancer, Hypoxia, and Metabolism and Ferroptosis and cancer prognosis, together about 19.8% of its articles. Its main subfields are Molecular Biology. (generated from OpenAlex topic counts and CAS ranking data)
MedComm – Oncology is a peer-reviewed, multidisciplinary, online open access journal that publishes the high-impact clinical, basic and translational advances in all aspects of oncology, emphasizing on disclosing the molecular pathogenic mechanism of human cancer and suggesting new techniques for cancer diagnosis and therapy. MedComm – Oncology provides a home for the clinical and experimental advances on solving clinical and scientific issues of cancer, concerning all aspects of cancer research, such as oncogenic mechanism, early screening/prevention, precise diagnosis and targeted therapy. MedComm – Oncology is also a multidisciplinary journal, covering disciplines including but not limited to clinical medicine, genetics, bioinformatics, molecular biology, cell biology, biological chemistry, pharmacology, medicinal chemistry and pharmacy. Researchers in these fields are welcome to submit their valuable work to MedComm – Oncology. Topics of interest include, but are not limited to: Cancer metabolism; Non-coding RNA; Cancer stem cell; Signal transduction; Tumour microenvironment and immunology; Early diagnosis and biomarkers; Drug discovery; Gene therapy, cell therapy and immunotherapy; Artificial intelligence.
From the journal's Aims & Scope
Research area (LetPub): Biochemistry, Genetics and Molecular Biology-Biochemistry, Genetics and Molecular Biology (miscellaneous)
Editor-in-chief Guido KroemerPublisher website
Editorial board by country: 20 in mainland China (about 36%); most named Mainland China 20, United States 11, France 5, United Kingdom 3, Italy 3 (55 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer Immunotherapy and BiomarkersMedicine8.1%
- Cancer, Hypoxia, and MetabolismBiochemistry, Genetics and Molecular Biology5.9%
- Ferroptosis and cancer prognosisMedicine5.9%
- Nanoplatforms for cancer theranosticsEngineering5.5%
- Epigenetics and DNA MethylationBiochemistry, Genetics and Molecular Biology5.1%
- Cancer Cells and MetastasisMedicine5.1%
- Cancer Research and TreatmentsBiochemistry, Genetics and Molecular Biology5.1%
- RNA modifications and cancerBiochemistry, Genetics and Molecular Biology4.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Not covered
Not covered by this edition.
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
Web of ScienceCASPublisher website
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher)
- 8.5Publisher website ·
- Impact factor (publisher) 2025
- 8.5Publisher website ·
- CiteScore 2026-06
- 5.3LetPub ·
- CiteScore (publisher)
- 5.3Publisher website ·
- CiteScore (publisher) 2025
- 5.3Publisher website ·
- SJR 2026-06
- 1.5LetPub ·
- SNIP 2026-06
- 0.87LetPub ·
- h-index
- 20OpenAlex ·
- i10-index
- 30OpenAlex ·
- 2-year mean citedness
- 5.33OpenAlex ·
- Self-citation rate
- 1.2%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 31LetPub ·
- Articles per year (publisher) 2025
- 41Publisher website ·
- Downloads per year (publisher) 2025
- 102,523Publisher website ·
Articles by year OpenAlex count · 211 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 54 | 54 | 22 |
| 2025 | 51 | 51 | 156 |
| 2024 | 45 | 45 | 621 |
| 2023 | 46 | 46 | 463 |
| 2022 | 15 | 15 | 62 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
127 daysMedian, submission to acceptance · P25–P75 90 days – 166 days
- Acceptance to online
- median 37 days (90 articles)
- Submission to online
- median 168 days
- Sample
- 90 articles with submission and acceptance dates (107 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 15 weeksLetPub ·
- Acceptance rate (publisher)
- 25%Publisher website ·
- Acceptance rate (publisher) 2025
- 25%Publisher website ·
- Submission to first decision
- 7 daysPublisher website ·
- Submission to first decision 2025
- 7 daysPublisher website ·
- Submission to acceptance 2025
- 140 daysPublisher website ·
- Acceptance to publication 2025
- 47 daysPublisher website ·
- Submission to publication (journal-reported)
- about 15 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 2,600 / GBP 2,160 / EUR 2,490 | Yes | CC BY | |
| OpenAlex | USD 0 | — | — | |
| LetPub | USD 2,800 | Yes | — | |
| Publisher website | Yes, amount not published | — | — |
Other charges and waivers (author guidelines)
- Submission fee
- Charged; see the journal's website for the amount
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare8 items from the author guidelines
- Abstract
- ≤ 200 words
- Keywords
- 3–6
- Manuscript length
- ≤ 6,000 words
- Reference style
- AMA
- First submission
- Free format: the journal's layout is not required
- Highlights
- Optional
- Graphical abstract
- Optional
- Cover letter
- Optional
Article types accepted10, with length limits
- editorialOriginal article is the full-length report of current research within any area covered in the journal’s scope, and aims to address novel findings and make signi…main text ≤ 1,000 words
- editorialsEditorials are the most important statement and opinions of global opinion leaders in relevant specialties and specially invited by the Editor, but unsolicited …Length not stated
- highlightHighlight aims to point the MedComm - Oncology readership to the latest novel findings published in other high-impact journals. Research Highlight should contai…Length not stated
- letterOriginal article is the full-length report of current research within any area covered in the journal’s scope, and aims to address novel findings and make signi…main text ≤ 1,200 words
- opinionOriginal article is the full-length report of current research within any area covered in the journal’s scope, and aims to address novel findings and make signi…Length not stated
- original articleOriginal article is the full-length report of current research within any area covered in the journal’s scope, and aims to address novel findings and make signi…Length not stated
- perspectiveOriginal article is the full-length report of current research within any area covered in the journal’s scope, and aims to address novel findings and make signi…main text ≤ 3,000 words
- research articleOriginal article is the full-length report of current research within any area covered in the journal’s scope, and aims to address novel findings and make signi…main text ≤ 6,000 words
- reviewOriginal article is the full-length report of current research within any area covered in the journal’s scope, and aims to address novel findings and make signi…Length not stated
- viewpointOriginal article is the full-length report of current research within any area covered in the journal’s scope, and aims to address novel findings and make signi…Length not stated
Policy excerpts from the journal's websiteAuthorship, Conflicts of interest, Data availability, Open access, Peer review, Preprints
- Authorship Authorship and Author Contribution
All listed authors should have contributed to the manuscript substantially and have agreed to the final submitted version.
Source ↗Publisher website ·- Conflicts of interest Conflict of Interest Statement
Authors will be asked to provide a conflict of interest statement during the submission process. Any interest or relationship, financial or otherwise that might be perceived as influencing an author's objectivity is considered a potential source of conflict of interest. These must be disclosed when directly relevant or directly related to the work that the authors describe in their manuscript. Pot…
Source ↗Publisher website ·- Data availability Data Sharing and Data Accessibility
Data Citation Model summary
Please review Wiley’s policy here. This journal encourages data sharing.
Source ↗Publisher website ·- Open access Understanding Open Access
As an open access journal, all articles in MedComm – Oncology are freely available to read, download and share immediately on publication.
Source ↗Publisher website ·- Peer review Peer Review and Acceptance
Peer Review and Acceptance Model summary
The acceptance criteria for all papers are the quality and originality of the research and its significance to journal readership. Except where otherwise stated, manuscripts are single-blind peer reviewed by two reviewers. Papers will only be sent to review if the Editor-in-Chief determines that the paper meets the appropriate quality and relevance requirements.
Source ↗Publisher website ·- Preprints
Preprint policy Model summary
This journal considers article previously published on preprint servers. MedComm-Oncology will consider for review articles previously available as preprints. Authors are requested to update any pre-publication versions with a link to the final published article. Authors may also post the final published version of the article immediately after publication.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Wiley
- Country or region
- Australia
- Language
- English
- ISSN
- 2769-6448
- Society / sponsor
- Sichuan International Medical Exchange & Promotion Association
- Latest issue on the website
- Volume 5, Issue 3 (September 2026)
- Official links
- Journal homepage ↗LetPub
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about MedComm - Oncology
What CAS zone is MedComm - Oncology in?
In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of MedComm - Oncology?
The journal's website gives an impact factor of 8.5 (2025); this is the journal's own figure, as LetPub lists none for it; CiteScore 5.3, h-index 20.
How long does peer review take at MedComm - Oncology?
Based on the dates recorded on 90 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 127 days (interquartile range 90–166 days); authors report an average review time of about 15 weeks; the journal's website gives an acceptance rate of 25% (2025). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of MedComm - Oncology?
According to the journal's author guidelines: Abstract: ≤ 200 words; Keywords: 3–6; Manuscript length: ≤ 6,000 words; Reference style: AMA; First submission: Free format: the journal's layout is not required; Highlights: Optional; Graphical abstract: Optional; Cover letter: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of MedComm - Oncology based?
Of the 55 board members whose country the journal's board page names, 20 (about 36%) are in mainland China; the countries named most often are Mainland China (20), United States (11) and France (5). Counted from the institutions listed on the board page; for reference only.
Which databases index MedComm - Oncology?
According to LetPub and DOAJ records, MedComm - Oncology is indexed in ESCI, Scopus and DOAJ. The journal's website also lists Web of Science and CAS; that list has not been checked against each database.
Is MedComm - Oncology open access, and what is the APC?
MedComm - Oncology is a fully open-access journal. APC about USD 2,600.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .